Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.
January 30, 2022
Share
Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners for €2.2 billion on November 8, 2021. The total purchase price (represents an enterprise value on a cash and debt free basis) for Atos Medical amounts to €2.155 billion. The acquisition will be structured as a 100% cash payment financed through debt financing. Following the expected acquisition, Coloplast gains access to a new chronic care segment to be run as a separate strategic business unit operating on shared Coloplast infrastructure. Closing of the transaction is subject to customary regulatory approvals. The transaction is expected to close in Q2 2021/22. As of January 25, 2022, The transaction is targeted to close on January 31, 2022, as all relevant regulatory approvals have been received. The transaction is expected to be increasingly EPS accretive from 2022/23.
Moelis & Company (NYSE:MC) acted as financial advisor and Kromann Reumert acted as legal advisor to Coloplast A/S. Danske Bank will act as underwriter for the debt financing. Corporate partners Rasmus Kindlund (Stockholm), Mike Bienenfeld (London), and Fredrik Lindqvist (Stockholm). They were supported by Cole Smith (London), Nima Naderi (Stockholm), Daniel Bergman (London) and Ina Lunneryd (Brussels); and Sophia Astberg (Stockholm), Alex Reed (London), Erica Wesström (Stockholm), Thyra Taune (Stockholm) and Erik Samuelsson (Stockholm) of Linklaters acted as legal advisors to PAI Partners. Gleiss Lutz acted as legal advisor to Coloplast A/S. Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg, Klara Secher and Axel Lennartsson, Lisa Hörnqvist and Mario Saad, Karl-Hugo Engdahl and Karolina Fuhrman, Tove Lövgren Frisk, Jolinn Uhlin and Michaela Ådén, Elin Broman and Lina Österberg and Ulf Pyk and Kromann Reumert of Vinge acted as lead counsel for Coloplast. Frank Leijdesdorffand Marc Wiggers of Loyens & Loeff N.V. acted as legal advisor for Coloplast.
Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners on January 31, 2022.
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.;
- ostomy care products (36.8%): bags and equipment used following intestinal operations;
- wound care and skincare products (11.9%): wound dressings, bandages, creams and gels;
- voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).
COLOPLAST A/S 
